Discover how IFLI's targeted initiatives and innovative strategies are reshaping the landscape of Follicular Lymphoma research and treatment
.png)
Follicular Lymphoma (FL) continues to be an area of high unmet need, primarily due to its indolent yet incurable nature. Approximately 30% of FL patients will see their condition progress to a more aggressive form, such as Diffuse Large B-cell Lymphoma (DLBCL), within their lifetime. The disease's heterogeneity complicates the development of personalized and targeted therapies.
.png)
Led by follicular lymphoma (FL) renowned experts, we aim at designing research programs to identify and understand the cellular and molecular determinants of tumor heterogeneity driving FL progression, treatment resistance, and transformation.
Identifying and validating surrogate or ancillary biomarkers to improve diagnostic, and disease progression prediction, inform treatment selection, allow response monitoring and decrease time on ineffective therapies.
Leveraging innovation in NGS to diagnose relapse before clinical or radiological evidence, optimize treatment response and inform treatment selection.
Gather clinical and multi-omics data, aggregate patient-reported outcomes to advance new biomarker and therapeutic target identification. Provide data access to researchers and interested third parties to support the rapid advance of drug development.
Identify the most promising technology platforms and partner with start-up/biotech companies to accelerate the development of novel therapies to benefit FL.
Thank you for your interest in contacting us. Please fill out the form with your inquiry or feedback, and our team will promptly respond to assist you.
